MMI (Medical Microinstruments)

Medical Microinstruments (MMI) was founded in 2015 near Pisa and develops the Symani Surgical System, a robotic microsurgery platform with NanoWrist instruments, tremor reduction and motion scaling of up to 20x, designed to operate on structures such as nerves and vessels down to 0.2 mm in diameter. On October 8, 2026 it announced a $125 million Series D led by existing investor BioStar Capital, with new investors S3 Ventures and Angelini Ventures and an undisclosed strategic investor; the funds will support commercial expansion in the US and key global markets and clinical trials, including the REMIND study. According to the company, about 50 systems are installed and about 3,500 complex procedures have been performed. Its North American base is in Jacksonville, Florida, and its CEO is Mark Toland. The round follows a $75 million Series B in 2022, led by Deerfield, and a $110 million round in 2024, led by Fidelity.